Cullgen is a biopharmaceutical company that has developed protein degradation technology that utilizes the body's own natural protein disposal system to selectively and efficiently degrade and remove disease-causing proteins. Our technology, which we call uSMITE™ (ubiquitin-mediated, small molecule-induced target elimination) has the potential to address a broad range of intracellular disease targets, including those representing the up to 80% of proteins that cannot be addressed by existing small molecule therapies, commonly referred to as undruggable targets. In addition to using our uSMITE™ platform to build our own pipeline of protein degradation product candidates, we are also developing a portfolio of novel E3 ligands. You can learn more information about Cullgen on our website: www.Cullgen.com
Location: United States, California, San Diego
Employees: 51-200
Total raised: $121M
Founded date: 2018
Investors 2
Date | Name | Website |
06.01.2021 | 3E Biovent... | 3ebiovc.co... |
- | Octagon Ca... | octagoninv... |
Funding Rounds 4
Date | Series | Amount | Investors | Deal News |
09.05.2023 | Series C | $40M | - | finsmes.co... |
25.02.2021 | Series B | $50M | - | 3ebiovc.co... |
10.04.2019 | Series A | $16M | - | finsmes.co... |
01.03.2018 | Seed | $15M | - | finsmes.co... |
Mentions in press and media 17
Date | Title | Description | Source |
09.05.2023 | US-headquartered biotech firm Cullgen snaps $40m in Series C... | Biotech firm Cullgen, a clinical-stage biopharmaceutical company dedicated to the development of fir... | dealstreet... |
08.05.2023 | Cullgen closes $40M round to support their tech platform and... | - | connect.or... |
08.05.2023 | Cullgen Raises $40M in Financing | Cullgen, Inc., a San Diego, CA and Shangai, China-based biotechnology company developing small molec... | finsmes.co... |
25.06.2021 | Roth Capital Partners to Host a Virtual Healthcare Private C... | NEWPORT BEACH, Calif., June 25, 2021 (GLOBE NEWSWIRE) -- via InvestorWire -- Roth Capital Partners (... | marketscre... |
25.02.2021 | Cullgen Closes $50 Million Series B Investment to Advance Ta... | SAN DIEGO & SHANGHAI--(BUSINESS WIRE)--Feb 25, 2021-- Cullgen Inc., a leading biotechnology com... | oaoa.com/n... |
25.02.2021 | CULLGEN CLOSES $50 MILLION SERIES B INVESTMENT TO ADVANCE TA... | - | 3ebiovc.co... |
25.02.2021 | Cullgen Completes $50M Series B Financing | SAN DIEGO, CA, Cullgen today announced that it has closed a $50 million Series B financing (assumi... | vcnewsdail... |
25.02.2021 | Cullgen has raised $50M in a Series B to support the develop... | - | connect.or... |
14.04.2019 | Biotech Startup Cullgen Raises $16M Series A | Cullgen, a San Diego-based biotechnology company, raised $16 million in a series A funding round led... | sdbj.com/n... |
11.04.2019 | Insurance Tech Startup Lemonade Raises $300 Million in Fundi... | MAKING LEMONADE Softbank is doubling down on Lemonade. Paid Content You can't secure what you can'... | fortune.co... |
Show more